Repligen Corporation (NASDAQ: RGEN) and Advanced Accelerator Applications (NASDAQ:AAAP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.
This is a summary of current ratings and target prices for Repligen Corporation and Advanced Accelerator Applications, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Advanced Accelerator Applications||0||1||4||0||2.80|
Repligen Corporation currently has a consensus price target of $46.00, indicating a potential upside of 26.97%. Advanced Accelerator Applications has a consensus price target of $56.50, indicating a potential downside of 20.69%. Given Repligen Corporation’s higher possible upside, research analysts plainly believe Repligen Corporation is more favorable than Advanced Accelerator Applications.
Volatility and Risk
Repligen Corporation has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Advanced Accelerator Applications has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
This table compares Repligen Corporation and Advanced Accelerator Applications’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Advanced Accelerator Applications||-33.83%||-16.05%||-11.18%|
Insider and Institutional Ownership
96.5% of Repligen Corporation shares are owned by institutional investors. Comparatively, 37.5% of Advanced Accelerator Applications shares are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Repligen Corporation and Advanced Accelerator Applications’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Repligen Corporation||$113.32 million||11.94||$29.54 million||$0.51||71.04|
|Advanced Accelerator Applications||N/A||N/A||N/A||($0.88)||-80.95|
Repligen Corporation has higher revenue and earnings than Advanced Accelerator Applications. Advanced Accelerator Applications is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.
Repligen Corporation beats Advanced Accelerator Applications on 9 of the 11 factors compared between the two stocks.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
Advanced Accelerator Applications Company Profile
Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with our FREE daily email newsletter.